Business Model:

BigDNA completed an investment of £1.5 million in October 2008 from an international consortium of institutional and individual investors. This was followed by a further investment of £2 million in February 2010. This investment was put in place to establish a strategy for the Company’s product and platform development.

BigDNA’s business model is to develop its human vaccine pipeline to Phase I/II and then to partner with a larger organisation with the required infrastructure to bring the product(s) to market.

The Company intends to out-licence its platform delivery technology in the veterinary and aquaculture fields. Out-licensing of the ‘core’ human applications of the technology will only be undertaken if strategically beneficial to the Company, so as to retain maximal value in the platform.